Clinical characteristics of patients with positive AM scintigraphy, in whom the treatment was modified from the time of evaluation
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | |
|---|---|---|---|---|---|---|---|
| Disease | PAN | PAN | PAN | PAN | CS | PM | |
| Organs involved (other than the heart) | |||||||
| Lung | + | + | |||||
| Kidney | + | + | + | ||||
| Skin | + | ||||||
| Muscular | + | + | |||||
| Peripheral neuropathy | + | + | |||||
| Polyarthritis | + | ||||||
| GI tract | + | + | + | ||||
| Raynaud | |||||||
| Treatments started from the time of evaluation (including AM scintigraphy) | CS 15 mg/kg | CS 500 mg | CS 1 mg/kg | CS 500 mg | CS 1 mg/kg | CS 1 mg/kg | |
| CYC 0.6 g/m2 | PE | CYC 0.6 g/m2 | CYC 1 g | CYC 0.6 g/m2 | |||
| PE | VB 15 mg/kg | CCB 50 mg/d | |||||
| ACEI 7.5 mg/d | ACEI 25 mg/d | ||||||
| CCB 50 mg/d | |||||||
| 7 | 8 | 9 | 10 |
|---|---|---|---|
| PM | Scl | PR | Lupus |
| + | |||
| + | |||
| + | + | ||
| + | |||
| + | + | ||
| + | |||
| CS 750 mg | Iloprost IV | CS 0.5 mg/kg | CS 60 mg |
| Penicillamine | MTX 15 mg | ACEI 5 mg/d | |
| Amiodarone | CSP 200 mg/d | Furosemide 40 mg/d | |
| ACEI 5 mg/j | ACEI 5 mg/d | ||
PAN: periarteritis nodosa. CS: Churg-Strauss syndrome. PM: polymyositis. Scl: systemic sclerosis. GI tract: gastrointestinal tract. CS (dose per day): prednisone. CYC (dose per month): cyclophosphamide. MTX (dose per week): methotrexate. CSP: cyclosporine. VB: vidarabine. PE: plasmatic exchanges. ACEI: angiotensin converting enzyme inhibitor. CCB: calcium channel blocker.